These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 24725026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
    Du X, Gao N, Song X.
    Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
    [Abstract] [Full Text] [Related]

  • 3. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
    Ahmed OA, Badr-Eldin SM.
    Int J Nanomedicine; 2018 Dec; 13():6325-6335. PubMed ID: 30349253
    [Abstract] [Full Text] [Related]

  • 4. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
    Rukmangathen R, Yallamalli IM, Yalavarthi PR.
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
    [Abstract] [Full Text] [Related]

  • 5. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
    Bagre AP, Jain K, Jain NK.
    Int J Pharm; 2013 Nov 01; 456(1):31-40. PubMed ID: 23994363
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug/HP-β-cyclodextrin inclusion complexes.
    Lu R, Liu S, Wang Q, Li X.
    Pharmazie; 2015 Dec 01; 70(12):791-7. PubMed ID: 26817276
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
    Wang X, Chi N, Tang X.
    Eur J Pharm Biopharm; 2008 Nov 01; 70(3):735-40. PubMed ID: 18684400
    [Abstract] [Full Text] [Related]

  • 10. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
    Hanafy AS, Farid RM, ElGamal SS.
    Drug Dev Ind Pharm; 2015 Nov 01; 41(12):2055-68. PubMed ID: 26133084
    [Abstract] [Full Text] [Related]

  • 11. Preparation and optimization of PMAA-chitosan-PEG nanoparticles for oral drug delivery.
    Pawar H, Douroumis D, Boateng JS.
    Colloids Surf B Biointerfaces; 2012 Feb 01; 90():102-8. PubMed ID: 22037474
    [Abstract] [Full Text] [Related]

  • 12. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
    Shahnaz G, Vetter A, Barthelmes J, Rahmat D, Laffleur F, Iqbal J, Perera G, Schlocker W, Dünnhaput S, Augustijns P, Bernkop-Schnürch A.
    Int J Pharm; 2012 May 30; 428(1-2):164-70. PubMed ID: 22421322
    [Abstract] [Full Text] [Related]

  • 13. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
    Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, Ali J.
    Eur J Pharm Sci; 2012 Aug 30; 47(1):6-15. PubMed ID: 22561106
    [Abstract] [Full Text] [Related]

  • 14. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
    Kanade R, Boche M, Pokharkar V.
    AAPS PharmSciTech; 2018 Apr 30; 19(3):1105-1115. PubMed ID: 29181706
    [Abstract] [Full Text] [Related]

  • 15. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
    Shah N, Seth A, Balaraman R, Sailor G, Javia A, Gohil D.
    Drug Dev Ind Pharm; 2018 Apr 30; 44(4):687-696. PubMed ID: 29168671
    [Abstract] [Full Text] [Related]

  • 16. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
    Jain A, Sharma T, Kumar R, Katare OP, Singh B.
    Drug Deliv Transl Res; 2022 May 30; 12(5):1136-1160. PubMed ID: 33966178
    [Abstract] [Full Text] [Related]

  • 17. Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment.
    Nagai N, Ogata F, Otake H, Nakazawa Y, Kawasaki N.
    Int J Nanomedicine; 2018 May 30; 13():5215-5229. PubMed ID: 30233182
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.
    Sharma M, Sharma R, Jain DK, Saraf A.
    Int J Biol Macromol; 2019 Aug 15; 135():246-260. PubMed ID: 31128197
    [Abstract] [Full Text] [Related]

  • 19. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism.
    Ravi PR, Aditya N, Kathuria H, Malekar S, Vats R.
    Eur J Pharm Biopharm; 2014 May 15; 87(1):114-24. PubMed ID: 24378615
    [Abstract] [Full Text] [Related]

  • 20. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation.
    Aditya N, Ravi PR, Avula US, Vats R.
    J Microencapsul; 2014 May 15; 31(5):508-18. PubMed ID: 24697167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.